Luokung Technology Corp.: 2025 Operating Revenue Up 9.9% YoY to 8.212 Billion Yuan, Innovative Drugs and Exclusive Drugs Become Core Growth Engines

Recently, Kangzhe Pharmaceutical released its annual performance report for the year ending December 31, 2025. During the reporting period, the company’s revenue increased by 9.9% to 8.212 billion yuan, compared to 7.469 billion yuan in the same period last year. If calculated based on drug sales revenue, the revenue grew by 8.9% to 9.386 billion yuan, mainly due to the continued growth of innovative and exclusive products.

Gross profit increased by 8.3% to 5.872 billion yuan, from 5.422 billion yuan last year; normalized annual profit grew by 3.6% to 1.776 billion yuan, compared to 1.714 billion yuan last year. Annual net profit decreased by 10.5% to 1.443 billion yuan, mainly due to the impact of one-time non-operating items. Basic earnings per share declined by 7.8% to 0.6154 yuan. The proposed final dividend is 0.1366 yuan per share, with a total annual dividend of 0.2921 yuan per share, a 9.0% increase from last year.

Management’s discussion and analysis section highlights that the company’s strategic transformation has achieved significant results, with innovative and exclusive drugs becoming the core growth engines, and product structure continuously optimized. The proportion of main exclusive/brand drugs and innovative drugs in total revenue increased to 59.8%. In terms of business segments, the skin health line achieved revenue of 1.07 billion yuan, a 73.2% increase compared to the same period last year.

(Kangzhe Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare